Global Benign Prostatic Hyperplasia (BPH) Drugs Market Professional Research Report 2014-2026, Segmented by Players, Types, End-Users in Major 40 Countries or Regions

Jun 02, 2020  |  152 PAGES  |  REPORT CODE: CMM309200
  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • INDUSTRY COVERAGE

The Benign Prostatic Hyperplasia (BPH) Drugs is expected to grow from USD XX.0 million in 2018 to USD XX.0 million by 2025, at a Compound Annual Growth Rate (CAGR) of 5.2% during the forecast period. The research provides insights for the global Benign Prostatic Hyperplasia (BPH) Drugs market based on different Types, End-Users and Regions, and competitive landscape of these segments are analyzed in detail.

A wide range of market influence factors are taken into consideration in the analysis, and potential developing factors for different Types, End-Users and Regions are also included in the report in order to figure out the most promising development trends in the Benign Prostatic Hyperplasia (BPH) Drugs industry. For presenting the most potential investment fields in North America, Europe, Asia Pacific and Latin America, Middle East & Africa, the market capacity and consumption potential of more than 34 major powers are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

The Snapshot of Global Benign Prostatic Hyperplasia (BPH) Drugs Market Segmentations:

By Players:

  • Astellas Pharma

  • Eli Lilly

  • GlaxoSmithKline

  • Sanofi

  • ADC Therapeutics

  • Bayer HealthCare

  • Bristol-Myers Squibb

  • Valeant Pharmaceuticals

  • Endo Pharmaceuticals

  • Foresee Pharmaceuticals

By Types:

  • Alpha-Blocker

  • Phosphodiesterase Type-5 Inhibitors

  • 5-Alpha-Reductase Inhibitors

By End-User:

  • Men

  • Women

By Regions:

North America

  • United States

  • Canada

  • Mexico

Europe

  • Germany

  • UK

  • France

  • Italy

  • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

  • Spain

  • Belgium

  • Poland

  • Russia

  • Turkey

  • Others

Asia-Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia and New Zealand

  • ASEAN Countries (Indonesia, Thailand, Malaysia, Singapore, Philippines, Vietnam, Others)

Latin America, Middle East & Africa

  • GCC Countries (Saudi Arabia, United Arab Emirates, Qatar, Others)

  • Brazil

  • Nigeria

  • South Africa

  • Argentina

  • Others

Table of Contents

1 Report Overview

  • 1.1 Product Definition and Scope

  • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Benign Prostatic Hyperplasia (BPH) Drugs Market

  • 1.3 Market Segmentation by Type

    • 1.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Alpha-Blocker from 2014 to 2026

    • 1.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Phosphodiesterase Type-5 Inhibitors from 2014 to 2026

    • 1.3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of 5-Alpha-Reductase Inhibitors from 2014 to 2026

  • 1.4 Market Segmentation by End-Users

    • 1.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Men from 2014 to 2026

    • 1.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Women from 2014 to 2026

  • 1.5 Market Segmentation by Regions

    • 1.5.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.1.1 United States Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.1.2 Canada Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.1.3 Mexico Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

    • 1.5.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.2.1 Germany Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.2.2 UK Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.2.3 France Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.2.4 Italy Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.2.5 Nordic Countries Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.2.6 Spain Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.2.7 Belgium Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.2.8 Poland Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.2.9 Russia Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.2.10 Turkey Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

    • 1.5.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.3.1 China Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.3.2 Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.3.3 Australia and New Zealand Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.3.4 India Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.3.5 ASEAN Countries Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.3.6 South Korea Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

    • 1.5.4 Latin America, Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.4.1 GCC Countries Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.4.2 Brazil Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.4.3 Nigeria Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.4.4 South Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.4.5 Argentina Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

2 Market Trends and Competitive Landscape

  • 2.1 Market Trends and Dynamics

    • 2.1.1 Market Challenges and Restraints 

    • 2.1.2 Market Opportunities and Potentials

    • 2.1.3 Mergers and Acquisitions

  • 2.2 Competitive Landscape Analysis

    • 2.2.1 Industrial Concentration Analysis

    • 2.2.2 Porter's Five Forces Analysis of the Industry

    • 2.2.3 SWOT Analysis for New Entrants

3 Segmentation of Benign Prostatic Hyperplasia (BPH) Drugs Market by Types

  • 3.1 Product Development Trends of Different Types

  • 3.2 Commercial Product Types of Major Vendors

  • 3.3 Competitive Landscape Analysis of Different Types

  • 3.4 Market Size of Benign Prostatic Hyperplasia (BPH) Drugs by Major Types

    • 3.4.1 Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Alpha-Blocker

    • 3.4.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Phosphodiesterase Type-5 Inhibitors

    • 3.4.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of 5-Alpha-Reductase Inhibitors

4 Segmentation of Benign Prostatic Hyperplasia (BPH) Drugs Market by End-Users

  • 4.1 Downstream Client Analysis by End-Users

  • 4.2 Competitive Landscape Analysis of Different End-Users

  • 4.3 Market Potential Analysis of Different End-Users

  • 4.4 Market Size of Benign Prostatic Hyperplasia (BPH) Drugs by Major End-Users

    • 4.4.1 Market Size and Growth Rate of Benign Prostatic Hyperplasia (BPH) Drugs in Men

    • 4.4.2 Market Size and Growth Rate of Benign Prostatic Hyperplasia (BPH) Drugs in Women

5 Market Analysis by Major Regions

  • 5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Production Analysis by Major Regions

  • 5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Analysis by Major Regions

  • 5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export Analysis by Regions

    • 5.3.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export Analysis 

    • 5.3.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export Analysis

    • 5.3.3 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export Analysis

    • 5.3.4 Latin America, Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export Analysis

6 Product Commodity of Benign Prostatic Hyperplasia (BPH) Drugs Market in Major Countries

  • 6.1 Top 5 Export Countries in Benign Prostatic Hyperplasia (BPH) Drugs market from 2014 to 2019

    • 6.1.1 Top 5 Export Countries' Export Value Analysis in Benign Prostatic Hyperplasia (BPH) Drugs market from 2014 to 2019

    • 6.1.2 Top 5 Export Countries'  Export Volume Analysis in Benign Prostatic Hyperplasia (BPH) Drugs market from 2014 to 2019

  • 6.2 Top 5 Import Countries in Benign Prostatic Hyperplasia (BPH) Drugs market from 2014 to 2019

    • 6.2.1 Top 5 Import Countries' Import Value Analysis in Benign Prostatic Hyperplasia (BPH) Drugs market from 2014 to 2019

    • 6.2.2 Top 5 Import Countries' Import Volume Analysis in Benign Prostatic Hyperplasia (BPH) Drugs market from 2014 to 2019

  • 6.3 Emerging Top 3 Export Countries Analysis

  • 6.4 Emerging Top 3 Import Countries Analysis

7 North America Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis

  • 7.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Types

  • 7.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major End-Users

  • 7.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Countries

    • 7.3.1 United States Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate

    • 7.3.2 Canada Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate

    • 7.3.3 Mexico Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate

8 Europe Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis

  • 8.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Types

  • 8.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major End-Users

  • 8.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Countries

    • 8.3.1 Germany Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate

    • 8.3.2 UK Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate

    • 8.3.3 France Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate

    • 8.3.4 Italy Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate

    • 8.3.5 Nordic Countries Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate

    • 8.3.6 Spain Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate

    • 8.3.7 Belgium Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate

    • 8.3.8 Poland Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate

    • 8.3.9 Russia Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate

    • 8.3.10 Turkey Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate

9 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis

  • 9.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Types

  • 9.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major End-Users

  • 9.3 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Countries

    • 9.3.1 China Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate

    • 9.3.2 Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate

    • 9.3.3 Australia and New Zealand Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate

    • 9.3.4 India Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate

    • 9.3.5 ASEAN Countries Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate

    • 9.3.6 South Korea Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate

10 Latin America, Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis

  • 10.1 Latin America, Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Types

  • 10.2 Latin America, Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major End-Users

  • 10.3 Latin America, Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Countries

    • 10.3.1 GCC Countries Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate

    • 10.3.2 Brazil Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate

    • 10.3.3 Nigeria Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate

    • 10.3.4 South Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate 

    • 10.3.5 Argentina Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate

11 Major Players Profile

  • 11.1 Astellas Pharma

    • 11.1.1 Astellas Pharma Company Profile and Recent Development

    • 11.1.2 Market Performance

    • 11.1.3 Product and Service Introduction

  • 11.2 Eli Lilly

    • 11.2.1 Eli Lilly Company Profile and Recent Development

    • 11.2.2 Market Performance

    • 11.2.3 Product and Service Introduction

  • 11.3 GlaxoSmithKline

    • 11.3.1 GlaxoSmithKline Company Profile and Recent Development

    • 11.3.2 Market Performance

    • 11.3.3 Product and Service Introduction

  • 11.4 Sanofi

    • 11.4.1 Sanofi Company Profile and Recent Development

    • 11.4.2 Market Performance

    • 11.4.3 Product and Service Introduction

  • 11.5 ADC Therapeutics

    • 11.5.1 ADC Therapeutics Company Profile and Recent Development

    • 11.5.2 Market Performance

    • 11.5.3 Product and Service Introduction

  • 11.6 Bayer HealthCare

    • 11.6.1 Bayer HealthCare Company Profile and Recent Development

    • 11.6.2 Market Performance

    • 11.6.3 Product and Service Introduction

  • 11.7 Bristol-Myers Squibb

    • 11.7.1 Bristol-Myers Squibb Company Profile and Recent Development

    • 11.7.2 Market Performance

    • 11.7.3 Product and Service Introduction

  • 11.8 Valeant Pharmaceuticals

    • 11.8.1 Valeant Pharmaceuticals Company Profile and Recent Development

    • 11.8.2 Market Performance

    • 11.8.3 Product and Service Introduction

  • 11.9 Endo Pharmaceuticals

    • 11.9.1 Endo Pharmaceuticals Company Profile and Recent Development

    • 11.9.2 Market Performance

    • 11.9.3 Product and Service Introduction

  • 11.10 Foresee Pharmaceuticals

    • 11.10.1 Foresee Pharmaceuticals Company Profile and Recent Development

    • 11.10.2 Market Performance

    • 11.10.3 Product and Service Introduction

12 Data Source and Research Methodology

The List of Tables and Figures (Totals 109 Figures and 133 Tables)

  • Figure Product Picture

  • Figure Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Alpha-Blocker from 2014 to 2026

  • Figure Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Phosphodiesterase Type-5 Inhibitors from 2014 to 2026

  • Figure Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of 5-Alpha-Reductase Inhibitors from 2014 to 2026

  • Figure Market Share by Type in 2014

  • Figure Market Share by Type in 2018

  • Figure Market Share by Type in 2026

  • Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Men from 2014 to 2026

  • Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Women from 2014 to 2026

  • Figure Market Share by End-User in 2014

  • Figure Market Share by End-User in 2018

  • Figure Market Share by End-User in 2026

  • Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Canada Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Mexico Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Germany Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure UK Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure France Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Italy Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Nordic Countries Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Spain Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Belgium Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Poland Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Russia Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Turkey Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Australia and New Zealand Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure India Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure ASEAN Countries Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure South Korea Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Latin America, Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure GCC Countries Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Brazil Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Nigeria Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure South Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Argentina Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Development Trends and Industry Dynamics of Benign Prostatic Hyperplasia (BPH) Drugs Industry

  • Figure Market Challenges and Restraints

  • Figure Market Opportunities and Potentials

  • Table Mergers and Acquisition

  • Figure Market Share of TOP 3 Players in 2018

  • Figure Market Share of TOP 5 Players in 2018

  • Figure Market Share of TOP 6 Players from 2014 to 2019

  • Figure Porter's Five Forces Analysis

  • Figure New Entrant SWOT Analysis

  • Table Specifications of Different Types of Benign Prostatic Hyperplasia (BPH) Drugs

  • Figure Development Trends of Different Types

  • Table Commercial Products Types of Major Vendors

  • Figure Competitive Landscape Analysis of Different Types

  • Table Consumption of Benign Prostatic Hyperplasia (BPH) Drugs by Different Types from 2014 to 2026

  • Table Consumption Share of Benign Prostatic Hyperplasia (BPH) Drugs by Different Types from 2014 to 2026

  • Figure Market Size and Growth Rate of Alpha-Blocker

  • Figure Market Size and Growth Rate of Phosphodiesterase Type-5 Inhibitors

  • Figure Market Size and Growth Rate of 5-Alpha-Reductase Inhibitors

  • Table Downstream Client Analysis by End-Users

  • Figure Competitive Landscape Analysis of Different End-Users

  • Table Market Potential Analysis of Different End-Users

  • Table Consumption of Benign Prostatic Hyperplasia (BPH) Drugs by Different End-Users from 2014 to 2026

  • Table Consumption Share of Benign Prostatic Hyperplasia (BPH) Drugs by Different End-Users from 2014 to 2026

  • Figure Market Size and Growth Rate of Men

  • Figure Market Size and Growth Rate of Women

  • Table Global Benign Prostatic Hyperplasia (BPH) Drugs Production by Major Regions

  • Table Global Benign Prostatic Hyperplasia (BPH) Drugs Production Share by Major Regions

  • Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Production Share by Major Regions in 2014

  • Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Production Share by Major Regions in 2018

  • Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Production Share by Major Regions in 2026

  • Table Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Major Regions

  • Table Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Major Regions

  • Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Major Regions in 2014

  • Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Major Regions in 2018

  • Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Major Regions in 2026

  • Table North America Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export Analysis

  • Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export Analysis

  • Table Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export Analysis

  • Table Latin America, Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export Analysis

  • Table Top 5 Export Countries' Export Value Analysis in Benign Prostatic Hyperplasia (BPH) Drugs market from 2014 to 2019

  • Table Top 5 Export Countries' Export Volume Analysis in Benign Prostatic Hyperplasia (BPH) Drugs market from 2014 to 2019

  • Table Top 5 Import Countries' Import Value Analysis in Benign Prostatic Hyperplasia (BPH) Drugs market from 2014 to 2019

  • Table Top 5 Import Countries' Import Volume Analysis in Benign Prostatic Hyperplasia (BPH) Drugs market from 2014 to 2019

  • Figure Emerging Top 3 Export Countries Analysis

  • Figure Emerging Top 3 Import Countries Analysis

  • Table North America Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Types from 2014 to 2026

  • Table North America Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types from 2014 to 2026

  • Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2014

  • Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2018

  • Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2026

  • Table North America Benign Prostatic Hyperplasia (BPH) Drugs Consumption by End-Users from 2014 to 2026

  • Table North America Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users from 2014 to 2026

  • Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2014

  • Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2018

  • Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2026

  • Table North America Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Major Countries from 2014 to 2026

  • Table North America Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Major Countries from 2014 to 2026

  • Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Major Countries in 2014

  • Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Major Countries in 2018

  • Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Major Countries in 2026

  • Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate from 2014 to 2026

  • Figure Canada Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate from 2014 to 2026

  • Figure Mexico Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate from 2014 to 2026

  • Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Types from 2014 to 2026

  • Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types from 2014 to 2026

  • Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2014

  • Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2018

  • Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2026

  • Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption by End-Users from 2014 to 2026

  • Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users from 2014 to 2026

  • Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2014

  • Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2018

  • Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2026

  • Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Major Countries from 2014 to 2026

  • Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Major Countries from 2014 to 2026

  • Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Major Countries in 2014

  • Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Major Countries in 2018

  • Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Major Countries in 2026

  • Figure Germany Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate from 2014 to 2026

  • Figure UK Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate from 2014 to 2026

  • Figure France Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate from 2014 to 2026

  • Figure Italy Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate from 2014 to 2026

  • Figure Nordic Countries Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate from 2014 to 2026

  • Figure Belgium Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate from 2014 to 2026

  • Figure Poland Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate from 2014 to 2026

  • Figure Russia Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate from 2014 to 2026

  • Figure Turkey Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate from 2014 to 2026

  • Table Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Types from 2014 to 2026

  • Table Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types from 2014 to 2026

  • Figure Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2014

  • Figure Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2018

  • Figure Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2026

  • Table Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Consumption by End-Users from 2014 to 2026

  • Table Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users from 2014 to 2026

  • Figure Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2014

  • Figure Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2018

  • Figure Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2026

  • Table Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Major Countries from 2014 to 2026

  • Table Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Major Countries from 2014 to 2026

  • Figure Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Major Countries in 2014

  • Figure Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Major Countries in 2018

  • Figure Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Major Countries in 2026

  • Figure China Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate from 2014 to 2026

  • Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate from 2014 to 2026

  • Figure Australia and New ZealandBenign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate from 2014 to 2026

  • Figure India Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate from 2014 to 2026

  • Figure ASEAN Countries Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate from 2014 to 2026

  • Figure South Korea Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate from 2014 to 2026

  • Table Latin America, Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Types from 2014 to 2026

  • Table Latin America, Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types from 2014 to 2026

  • Figure Latin America, Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2014

  • Figure Latin America, Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2018

  • Figure Latin America, Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2026

  • Table Latin America, Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption by End-Users from 2014 to 2026

  • Table Latin America, Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users from 2014 to 2026

  • Figure Latin America, Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2014

  • Figure Latin America, Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2018

  • Figure Latin America, Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2026

  • Table Latin America, Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Major Countries from 2014 to 2026

  • Table Latin America, Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Major Countries from 2014 to 2026

  • Figure Latin America, Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Major Countries in 2014

  • Figure Latin America, Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Major Countries in 2018

  • Figure Latin America, Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Major Countries in 2026

  • Figure GCC Countries Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate from 2014 to 2026

  • Figure Brazil Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate from 2014 to 2026

  • Figure Nigeria Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate from 2014 to 2026

  • Figure South Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate from 2014 to 2026

  • Figure Argentina Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate from 2014 to 2026

  • Table Company Profile and Development Status of Astellas Pharma

  • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Astellas Pharma

  • Figure Sales and Growth Rate Analysis of Astellas Pharma

  • Figure Revenue and Market Share Analysis of Astellas Pharma

  • Table Product and Service Introduction of Astellas Pharma

  • Table Company Profile and Development Status of Eli Lilly

  • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Eli Lilly

  • Figure Sales and Growth Rate Analysis of Eli Lilly

  • Figure Revenue and Market Share Analysis of Eli Lilly

  • Table Product and Service Introduction of Eli Lilly

  • Table Company Profile and Development Status of GlaxoSmithKline

  • Table Sales, Revenue, Sales Price and Gross Margin Analysis of GlaxoSmithKline

  • Figure Sales and Growth Rate Analysis of GlaxoSmithKline

  • Figure Revenue and Market Share Analysis of GlaxoSmithKline

  • Table Product and Service Introduction of GlaxoSmithKline

  • Table Company Profile and Development Status of Sanofi

  • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Sanofi

  • Figure Sales and Growth Rate Analysis of Sanofi

  • Figure Revenue and Market Share Analysis of Sanofi

  • Table Product and Service Introduction of Sanofi

  • Table Company Profile and Development Status of ADC Therapeutics

  • Table Sales, Revenue, Sales Price and Gross Margin Analysis of ADC Therapeutics

  • Figure Sales and Growth Rate Analysis of ADC Therapeutics

  • Figure Revenue and Market Share Analysis of ADC Therapeutics

  • Table Product and Service Introduction of ADC Therapeutics

  • Table Company Profile and Development Status of Bayer HealthCare

  • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Bayer HealthCare

  • Figure Sales and Growth Rate Analysis of Bayer HealthCare

  • Figure Revenue and Market Share Analysis of Bayer HealthCare

  • Table Product and Service Introduction of Bayer HealthCare

  • Table Company Profile and Development Status of Bristol-Myers Squibb

  • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Bristol-Myers Squibb

  • Figure Sales and Growth Rate Analysis of Bristol-Myers Squibb

  • Figure Revenue and Market Share Analysis of Bristol-Myers Squibb

  • Table Product and Service Introduction of Bristol-Myers Squibb

  • Table Company Profile and Development Status of Valeant Pharmaceuticals

  • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Valeant Pharmaceuticals

  • Figure Sales and Growth Rate Analysis of Valeant Pharmaceuticals

  • Figure Revenue and Market Share Analysis of Valeant Pharmaceuticals

  • Table Product and Service Introduction of Valeant Pharmaceuticals

  • Table Company Profile and Development Status of Endo Pharmaceuticals

  • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Endo Pharmaceuticals

  • Figure Sales and Growth Rate Analysis of Endo Pharmaceuticals

  • Figure Revenue and Market Share Analysis of Endo Pharmaceuticals

  • Table Product and Service Introduction of Endo Pharmaceuticals

  • Table Company Profile and Development Status of Foresee Pharmaceuticals

  • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Foresee Pharmaceuticals

  • Figure Sales and Growth Rate Analysis of Foresee Pharmaceuticals

  • Figure Revenue and Market Share Analysis of Foresee Pharmaceuticals

  • Table Product and Service Introduction of Foresee Pharmaceuticals


Report Purchase

reports
$4480
$8960
BUY NOWClick MeBUY NOW
top